Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/18/2025
-
TipRanks Financial Blog
8/15/2025
-
TipRanks Financial Blog
8/14/2025
-
TipRanks Financial Blog
8/14/2025
-
TipRanks Financial Blog
8/14/2025
-
TipRanks Financial Blog
8/13/2025
-
Fool.com Headlines
8/13/2025
-
Newsfile Corp. - News Releases
8/1/2025
-
Ticker Report
7/30/2025
-
MarketBeat
7/29/2025
-
GuruFocus
7/29/2025
-
TipRanks Financial Blog
7/29/2025
-
Ticker Report
7/28/2025
-
TipRanks Financial Blog
7/28/2025
-
Newsfile Corp. - News Releases
7/24/2025
-
MarketBeat
7/17/2025
-
TipRanks Financial Blog
7/8/2025
-
MarketBeat
6/26/2025
-
MarketBeat
6/26/2025
-
MarketBeat
6/5/2025
-
MarketBeat
6/2/2025
-
MarketBeat
5/23/2025
-
MarketBeat
5/18/2025
-
MarketBeat
5/16/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 12 3543 0000
Address
60 Jubilee Avenue
Abingdon, OX14 4RX
Abingdon, OX14 4RX
Country
Year Founded
Business Description
Sector
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops...
more